Daejeon
South Korea
9
2023-12-21
9
2025-11-25
These are the the leading inventors for applications assigned to IntoCell Inc.:
IntoCell Inc. based in Daejeon, KR has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:
COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF
#2 | 2022-11-03 ✅ Patent 12,606,625 granted on 2026-04-21ANTIBODY BINDING SPECIFICALLY TO B7-H3 AND USE THEREOF
#3 | 2022-05-26 ✅ Patent 11,807,628 granted on 2023-11-07Benzodiazepine derivatives and uses thereof
#4 | 2022-02-17 ✅ Patent 12,168,060 granted on 2024-12-17Antibody-drug conjugates comprising anti-B7-H3 antibodies
#5 | 2022-01-13 ✅ Patent 12,274,898 granted on 2025-04-15Substituted benzodiazepines as antibody-drug conjugates
#6 | 2021-12-23 ✅ Patent 12,551,570 granted on 2026-02-17COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF
#7 | 2021-12-16 ✅ Patent 11,753,431 granted on 2023-09-12Compounds comprising cleavable linker and uses thereof
#8 | 2019-12-05 ✅ Patent 11,084,801 granted on 2021-08-10Benzodiazepine derivatives and uses thereof
#9 | 2019-10-31 ✅ Patent 11,065,343 granted on 2021-07-20Compound bearing beta-galactoside-introduced self-immolative linker
Also check out IntoCell Inc.'s (Daejeon, South Korea) applicant profile with 10 patent applications submitted.
591243 ⎘